Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
With this, the total number of Patents granted to company for its innovative processes and technology stands at 9
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
Suven Pharmaceuticals’ API and forumulations facilities complete USFDA inspection successfully
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
Project achieves 30% reduction in hospital acquired infections and 24% reduction in the incidence of multi-drug resistant organisms
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
Subscribe To Our Newsletter & Stay Updated
